Reviewing Biogen (NASDAQ:BIIB) and Allena Pharmaceuticals (NASDAQ:ALNA)

Biogen (NASDAQ:BIIB) and Allena Pharmaceuticals (NASDAQ:ALNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Earnings and Valuation

This table compares Biogen and Allena Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biogen $13.45 billion 3.34 $4.43 billion $26.20 8.83
Allena Pharmaceuticals N/A N/A -$35.65 million ($1.72) -2.87

Biogen has higher revenue and earnings than Allena Pharmaceuticals. Allena Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.6% of Biogen shares are held by institutional investors. Comparatively, 79.7% of Allena Pharmaceuticals shares are held by institutional investors. 0.4% of Biogen shares are held by company insiders. Comparatively, 38.6% of Allena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Biogen and Allena Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen 2 24 6 0 2.13
Allena Pharmaceuticals 0 0 7 0 3.00

Biogen currently has a consensus target price of $277.36, suggesting a potential upside of 19.85%. Allena Pharmaceuticals has a consensus target price of $24.60, suggesting a potential upside of 397.98%. Given Allena Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Allena Pharmaceuticals is more favorable than Biogen.

Risk and Volatility

Biogen has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Profitability

This table compares Biogen and Allena Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biogen 33.79% 41.39% 21.63%
Allena Pharmaceuticals N/A -73.27% -57.31%

Summary

Biogen beats Allena Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.